PRPatricia Silvia Romano

Patricia Silvia Romano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patricia Silvia Romano has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • María Cristina Vanrell

    Laboratorio de Biología de Trypanosoma cruzi y la célula hospedadora - Instituto de Histología y Embriología “Dr. Mario H. Burgos”, IHEM-CONICET- Universidad Nacional de Cuyo, Mendoza, Argentina

    11 shared publications
  • Juan Agustín Cueto

    Instituto de Histología y Embriología “Dr. Mario H. Burgos”, IHEM-CONICET- Universidad Nacional de Cuyo

    8 shared publications
  • Betiana Nebaí Salassa

    Laboratorio de Biología de Trypanosoma cruzi y la célula hospedadora—Instituto de Histología y Embriología “Dr. Mario H. Burgos” IHEM‐CONICET—Universidad Nacional de Cuyo Mendoza Argentina

    6 shared publications
  • Carolina Carrillo

    Instituto de Ciencia y Tecnología Dr. César Milstein, ICT Milstein-CONICET, Buenos Aires, Argentina

    4 shared publications
  • María Isabel Colombo

    B Facultad de Ciencias Médicas , Universidad Nacional de Cuyo , Mendoza , Argentina

    4 shared publications
  • Ana Florencia Casassa

    A Laboratorio de Biología de Trypanosoma cruzi y la célula hospedadora- Instituto de Histología y Embriología "Dr. Mario H. Burgos" , (IHEM-CONICET- Universidad Nacional de Cuyo) , Mendoza , Argentina

    3 shared publications

Latest Publications

  • Open Access

    New insights for an old drug: difluoromethylornithine boosts the trypanocidal action of benznidazole on Trypanosoma cruzi in vitro and in vivo

    by Santiago José Martínez, Santiago José, María Cristina Vanrell, Xiaomo Li, Carolina Carrillo, David M. Engman, Patricia Silvia Romano

    Chagas disease, caused by the protozoan parasite Trypanosoma cruzi , is currently a global health problem. Its multiple forms of transmission, which favor the spread of the infection, and the limited treatment options—still restricted to only two drugs—highlight the urgent need for research and development in the field. Despite certain disadvantages, the potent trypanocidal activity of benznidazole (BNZ) and nifurtimox explains their continued use notwithstanding their high toxicity. Reducing BNZ doses through combination with another antiparasitic drug is an attractive strategy to improve tolerability while maintaining efficacy. In this work, we explored the anti- T. cruzi effect of BNZ in combination with difluoromethylornithine (DFMO), a repurposed drug currently used for the treatment of certain cancers and other pathologies. Our data showed that DFMO increases parasite susceptibility to BNZ, reducing the IC50 by half compared to BNZ monotherapy in vitro across strains from three different T. cruzi genetic lineages. Subsequently, we examined the effect of the combination in vivo . We found that mice treated with a 10-fold lower dose of BNZ combined with DFMO displayed a lower parasitemia peak and reduced tissue parasitosis during the acute stage, as well as less parasite reactivation in organs after immunosuppression in the chronic stage, compared to BNZ monotherapy. Overall, these findings support the BNZ/DFMO combination as a proof of concept for Chagas disease therapy, offering a viable strategy to mitigate BNZ-related toxicity through dose reduction without compromising therapeutic efficacy.


  • Insights into the Procedures and Interpretation of Autophagy in Trypanosoma cruzi

    by Gabriel Ferri, María Belén López, Juan Agustín Cueto, María Cristina Vanrell, Patricia Silvia Romano

    Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a life-threatening neglected illness endemic to Latin America. Despite efforts, it has recently become a global concern due to human migration from endemic to non-endemic areas. Exploring parasite pathways to interrupt the T. cruzi life cycle may lead to new treatments. In particular, autophagy plays a relevant role throughout its life cycle. In this context, the modulation of autophagy could provide multiple targets for new trypanocidal drugs. In this chapter, we describe various techniques developed to study autophagy in T. cruzi, such as fluorescence and electron microscopy to visualize autophagic structures in living or fixed parasites, and Western blotting to analyze autophagosome formation by tagging the LC3-like protein TcAtg8.1. The interpretation of these techniques allows for the distinction between changes in autophagic flux and specific differences in the steps of this pathway. Understanding the dynamics of autophagy in T. cruzi could assist researchers in exploring its potential role as a therapeutic target for Chagas disease.


  • The host Rab9a/Rab32 axis is actively recruited to the Trypanosoma cruzi parasitophorous vacuole and benefits the infection cycle

    by Betiana Nebaí Salassa, Juan Agustín Cueto, María Cristina Vanrell, María Belén López, Albert Descoteaux, Carlos Alberto Labriola, Patricia Silvia Romano

    Trypanosoma cruzi, the etiological agent of Chagas disease is a protozoan parasite that infects phagocytic and non‐phagocytic mammalian cells. At early stages of infection, trypomastigotes, the infective forms of this parasite, localize in a vesicular compartment called the T. cruzi parasitophorous vacuole until the exit of parasites to the host cell cytoplasm where continue their infective cycle. Rab proteins participate in the membrane traffic's molecular machinery, functioning as central regulators of vesicle recognition and transport. In previous work, we demonstrated that endocytic Rabs are key factors of the T. cruzi infection process in non‐phagocytic cells, regulating the formation and the maturation of the vacuole. In this work, we identified and characterized other molecular components of the vesicular transport pathways and their participation in the T. cruzi infection. We found that Rab9a and Rab32, two regulators of the endocytic and autophagic pathways, were actively recruited to the T. cruzi vacuoles and favored the late stages of the infective process. The recruitment was specific and dependent on T. cruzi protein synthesis. Interestingly, Rab32 association depends on the presence of Rab9a in the vacuolar membrane, while the inhibition of the cysteine‐protease cruzipain, a T. cruzi virulence factor, significantly decreases both Rab9a and Rab32 association with the vacuole. In summary, this work showed for the first time that specific molecules produced and secreted by the parasite can subvert intracellular components of host cells to benefit the infection. These new data shed light on the complex map of interactions between T. cruzi and the host cell and introduce concepts that can be useful in finding new forms of intervention against this parasite in the future.


  • Autophagy as an innate immunity response against pathogens: a Tango dance

    by Milton O. Aguilera, Laura R. Delgui, Fulvio Reggiori, Patricia S. Romano, María I. Colombo

    Intracellular infections as well as changes in the cell nutritional environment are main events that trigger cellular stress responses. One crucial cell response to stress conditions is autophagy. During the last 30 years, several scenarios involving autophagy induction or inhibition over the course of an intracellular invasion by pathogens have been uncovered. In this review, we will present how this knowledge was gained by studying different microorganisms. We intend to discuss how the cell, via autophagy, tries to repel these attacks with the objective of destroying the intruder, but also how some pathogens have developed strategies to subvert this. These two fates can be compared with a Tango , a dance originated in Buenos Aires, Argentina, in which the partner dancers are in close connection. One of them is the leader, embracing and involving the partner, but the follower may respond escaping from the leader. This joint dance is indeed highly synchronized and controlled, perfectly reflecting the interaction between autophagy and microorganism.


  • Open Access

    Close Encounters: Pathogenic Protists-Host Cell Interactions

    by María Cristina Vanrell, Patricia Silvia Romano

    In this chapter, we summarize the highlights of the early events in the interaction of parasitic protists and the host cell. Pathogenic protists are a group of eukaryotic organisms, responsible for causing different human diseases, such as malaria, Chagas disease, leishmaniasis, and toxoplasmosis. These pathogens display complex life cycles and go through different cellular transformations to adapt to the different hosts in which they live. Part of these life cycles takes place in mammals, inside the host cell. Host cell entry ends with the formation of phagosomes or parasitophorous vacuoles, which differ from each parasite and each type of host cell. While canonical phagocytosis involves the fusion of phagosomes with compartments of the endocytic pathway to produce normal maturation through the phagocytic route, pathogenic microorganisms have developed Different evasion mechanisms to resist the intracellular defense systems. These strategies, including phagosome maturation arrest, resistance to the harsh lysosomal environment, or exit to the host cell cytoplasm, will be also presented in this work.


  • Open Access

    Autophagy in protists and their hosts: When, how and why?

    by Patricia Silvia Romano, Takahiko Akematsu, Sébastien Besteiro, Annina Bindschedler, Vern B. Carruthers, Zeinab Chahine, Isabelle Coppens, Albert Descoteaux, Thabata Lopes Alberto Duque, Cynthia Y. He, et al.

    Pathogenic protists are a group of organisms responsible for causing a variety of human diseases including malaria, sleeping sickness, Chagas disease, leishmaniasis, and toxoplasmosis, among others. These diseases, which affect more than one billion people globally, mainly the poorest populations, are characterized by severe chronic stages and the lack of effective antiparasitic treatment. Parasitic protists display complex life-cycles and go through different cellular transformations in order to adapt to the different hosts they live in. Autophagy, a highly conserved cellular degradation process, has emerged as a key mechanism required for these differentiation processes, as well as other functions that are crucial to parasite fitness. In contrast to yeasts and mammals, protist autophagy is characterized by a modest number of conserved autophagy-related proteins (ATGs) that, even though, can drive the autophagosome formation and degradation. In addition, during their intracellular cycle, the interaction of these pathogens with the host autophagy system plays a crucial role resulting in a beneficial or harmful effect that is important for the outcome of the infection. In this review, we summarize the current state of knowledge on autophagy and other related mechanisms in pathogenic protists and their hosts. We sought to emphasize when, how, and why this process takes place, and the effects it may have on the parasitic cycle. A better understanding of the significance of autophagy for the protist life-cycle will potentially be helpful to design novel anti-parasitic strategies. Abbreviations: AAs: amino acids; ATGs: autophagy-related proteins; ADCD; autophagy-dependent cell death; AMPK: 5’ adenosine monophosphate-activated protein kinase; CD40: Cluster of differentiation 40; gHBSS: Hanks’ Balanced Salt Solution; GO: gene ontology; IFN-γ: IFN-gamma; LC3: mammalian microtubule-associated protein light chain 3; LAP; LC3-associated phagocytosis; LECA: last eukaryotic common ancestor; 3-MA: 3-methyladenine; MTOR; Mechanistic target of rapamycin kinase; MDC: monodansylcadaverine; NDP52: nuclear dot protein 52; PAAR: Plasmodium-Associated Autophagy-Related response; PE: phosphatidylethanolamine: PCD: programmed cell death; PND: programmed nuclear death; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PV: parasitophorous vacuole; PVM: parasitophorous vacuole membrane; SNARE: soluble N-ethylmaleimide-sensitive-factor attachment receptor; SQSTM1/p62: sequestosome-1; TEM: transmission electron microscopy; TNF-α: tumor necrosis factor-alpha; TVN: tubovesicular network; Ub: ubiquitin; UPS: ubiquitin-proteasome system; Vps: vacuolar protein sorting.


  • Open Access

    Induction of Autophagy by Ursolic Acid Promotes the Elimination of Trypanosoma cruzi Amastigotes From Macrophages and Cardiac Cells

    by María Cristina Vanrell, Santiago José Martinez, Lucila Ibel Muñoz, Betiana Nebaí Salassa, Julián Gambarte Tudela, Patricia Silvia Romano

    Chagas disease, caused by the parasite Trypanosoma cruzi, is an infectious illness endemic to Latin America and still lacks an effective treatment for the chronic stage. In a previous study in our laboratory, we established the protective role of host autophagy in vivo during T. cruzi infection in mice and proposed this process as one of the mechanisms involved in the innate immune response against this parasite. In the search for an autophagy inducer that increases the anti-T. cruzi response in the host, we found ursolic acid (UA), a natural pentacyclic triterpene with many biological actions including autophagy induction. The aim of this work was to study the effect of UA on T. cruzi infection in vitro in the late infection stage, when the nests of intracellular parasites are forming, in both macrophages and cardiac cells. To test this effect, the cells were infected with T. cruzi for 24 h and then treated with UA (5–10 µM). The data showed that UA significantly decreased the number of amastigotes found in infected cells in comparison with non-treated cells. UA also induced the autophagy response in both macrophages and cardiac cells under the studied conditions, and the inhibition of this pathway during UA treatment restored the level of infection. Interestingly, LC3 protein, the main marker of autophagy, was recruited around amastigotes and the acidic probe LysoTracker localized with them, two key features of xenophagy. A direct cytotoxic effect of UA was also found on trypomastigotes of T. cruzi, whereas epimastigotes and amastigotes displayed more resistance to this drug at the studied concentrations. Taken together, these data showed that this natural compound reduces T. cruzi infection in the later stages by promoting parasite damage through the induction of autophagy. This action, in addition to the effect of this compound on trypomastigotes, points to UA as an interesting lead for Chagas disease treatment in the future.


  • Open Access

    Biological features of TcM: A new Trypanosoma cruzi isolate from Argentina classified into TcV lineage

    by Santiago José Martinez, Gonzalo Nicolás Nardella, Matías Exequiel Rodríguez, Cynthia Vanesa Rivero, Fernán Agüero, Patricia Silvia Romano


  • Open Access

    Repurposing Carvedilol as a Novel Inhibitor of the Trypanosoma cruzi Autophagy Flux That Affects Parasite Replication and Survival

    by Cynthia Vanesa Rivero, Santiago José Martínez, Paul Novick, Juan Agustín Cueto, Betiana Nebaí Salassa, María Cristina Vanrell, Xiaomo Li, Carlos Alberto Labriola, Luis Mariano Polo, David M. Engman, et al.

    T. cruzi, the causal agent of Chagas disease, is a parasite able to infect different types of host cells and to persist chronically in the tissues of human and animal hosts. These qualities and the lack of an effective treatment for the chronic stage of the disease have contributed to the durability and the spread of the disease around the world. There is an urgent necessity to find new therapies for Chagas disease. Drug repurposing is a promising and cost-saving strategy for finding new drugs for different illnesses. In this work we describe the effect of carvedilol on T. cruzi. This compound, selected by virtual screening, increased the accumulation of immature autophagosomes characterized by lower acidity and hydrolytic properties. As a consequence of this action, the survival of trypomastigotes and the replication of epimastigotes and amastigotes were impaired, resulting in a significant reduction of infection and parasite load. Furthermore, carvedilol reduced the whole-body parasite burden peak in infected mice. In summary, in this work we present a repurposed drug with a significant in vitro and in vivo activity against T. cruzi. These data in addition to other pharmacological properties make carvedilol an attractive lead for Chagas disease treatment.


  • Open Access

    Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection

    by Xiaomo Li, Sijia Yi, Débora B. Scariot, Santiago J. Martinez, Ben A. Falk, Cheryl L. Olson, Patricia S. Romano, Evan A. Scott, David M. Engman

    Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi ( T . cruzi ), an intracellular pathogen that causes significant morbidity and death among millions in the Americas from Canada to Argentina. Current therapy involves oral administration of the nitroimidazole benznidazole (BNZ), which has serious side effects that often necessitate cessation of treatment. To both avoid off-target side effects and reduce the necessary dosage of BNZ, we packaged the drug within poly(ethylene glycol)-block-poly(propylene sulfide) polymersomes (BNZ-PSs). We show that these vesicular nanocarriers enhanced intracellular delivery to phagocytic cells and tested this formulation in a mouse model of T . cruzi infection. BNZ-PS is not only nontoxic but also significantly more potent than free BNZ, effectively reducing parasitemia, intracellular infection, and tissue parasitosis at a 466-fold lower dose of BNZ. We conclude that BNZ-PS was superior to BNZ for treatment of T . cruzi infection in mice and that further modifications of this nanocarrier formulation could lead to a wide range of custom controlled delivery applications for improved treatment of Chagas disease in humans.